US 11,858,924 B2
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
Jonas Brånalt, Gothenberg (SE); Maria Johansson, Gothenberg (SE); Anneli Nordqvist, Gothenberg (SE); and Marianne Swanson, Gothenberg (SE)
Assigned to AstraZeneca, Södertälje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Jun. 12, 2023, as Appl. No. 18/332,897.
Application 18/332,897 is a continuation of application No. PCT/IB2021/061839, filed on Dec. 16, 2021.
Claims priority of provisional application 63/126,593, filed on Dec. 17, 2020.
Prior Publication US 2023/0312550 A1, Oct. 5, 2023
Int. Cl. C07D 417/12 (2006.01); A61P 1/16 (2006.01)
CPC C07D 417/12 (2013.01) [A61P 1/16 (2018.01)] 13 Claims
 
1. A compound that is N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholino-quinoline-4-carboxamide having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.